help button home button JAMIA Hate scrolling?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First published June 25, 2008 as JAMIA PrePrint; doi:10.1197/jamia.M2605
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
M2605v1
15/5/581    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Kim, D.
Right arrow Articles by Holliday, S. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, D.
Right arrow Articles by Holliday, S. H.
J Am Med Inform Assoc. 2008;15:581-584. DOI 10.1197/jamia.M2605.
© 2008 American Medical Informatics Association

Case Report

Opportunities for Electronic Health Record Data to Support Business Functions in the Pharmaceutical Industry—A Case Study from Pfizer, Inc.

Daijin Kim, MBAa,c,*, Steven Labkoff, MDa and Samuel H. Holliday, BSEb,d

a Pfizer Healthcare Informatics, Pfizer Inc., New York, NY
b Accenture, Philadelphia, PA
c Columbia University, New York, NY
d University of Pennsylvania, Philadelphia, PA

* Correspondence: Daijin Kim, MBA, 235 East 42nd Street, New York, NY, 10017, Mailstop 235/14/9 (Email: daijin.kim{at}pfizer.com).

Received for publication: 08/22/07; accepted for publication: 06/06/08.

The Pfizer Healthcare Informatics team conducted a series of guided interviews with 35 Pfizer senior leaders to elicit their understanding, desires, and expectations of how Electronic Health Records (EHR) might be used in the pharmaceutical industry today and/or in the future. The interviews yielded fourteen use case categories comprising 42 specific use cases. The highest priority use cases were "Drug Safety & Surveillance," "Clinical Trial Recruitment," and "Support Regulatory Approval." Fifteen EHR companies were surveyed to assess their functionality against the specified use cases. Self-reported responses from the EHR companies were highest for "Virtual Phase IV Trials" and "Document Management for Clinical Trials." This research identifies preliminary opportunities for EHR products to provide aggregate, blinded data to address the interests of the pharmaceutical industry. However, further collaboration between the stakeholders will be necessary to ensure the full realization of the opportunities for data re-use.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Medical Informatics Association.